Jonathan Lewis

Jonathan Lewis joined Samus Therapeutics in March 2016. He brings to Samus a breadth of knowledge, expertise and innovation in both the biopharmaceutical industry and medicine. He served in executive roles, including Chairman and Chief Executive Officer, at ZIOPHARM Oncology for over 10 years, taking that company from a private start-up focused on novel small molecules in cancer to a publicly-listed company at the forefront of therapeutics development in immuno-oncology. Prior to ZIOPHARM, Dr. Lewis served as Chief Medical Officer of Antigenics (now Agenus). Dr. Lewis came to industry from academic medicine, and is a fellow of both the Royal College of Surgeons and the American College of Surgeons. He was awarded an MB.B.Ch. from University of the Witwatersrand School of Medicine, and his Ph.D. in Molecular Biology from Witwatersrand and Yale School of Medicine. He completed his Surgical Residency at University of Witwatersrand, University of Cambridge and at Yale-New Haven Hospital, ultimately becoming Professor of Surgery and Medicine at the Memorial Sloan Kettering Cancer Center. Dr. Lewis has also worked as a specialist advisor and board member for multiple biotechnology companies and non-profit organizations, including the Congressional Business Council, Hope Funds for Cancer Research, POPPA/NYPD, the Jackson Foundation Combat Wound Initiative Program, and the Yale Biotechnology and Pharma Society. He was Chairman of the Scientific Council, Chairman of the Board, and elected the first Life Trustee of the Hope Funds for Cancer Research, an organization dedicated to advancing research for the most difficult-to-treat cancers.